BR9714573A - Tratamento de laminite equina - Google Patents
Tratamento de laminite equinaInfo
- Publication number
- BR9714573A BR9714573A BR9714573-4A BR9714573A BR9714573A BR 9714573 A BR9714573 A BR 9714573A BR 9714573 A BR9714573 A BR 9714573A BR 9714573 A BR9714573 A BR 9714573A
- Authority
- BR
- Brazil
- Prior art keywords
- laminitis
- equine
- donor
- combinations
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
"TRATAMENTO DA LAMINITE EQuINA". São revelados composições e métodos do tratamento tópico da laminite eq³ina; em particular são descritas combinações de um doador de óxido nítrico (NO) de rápida atuação, um doador de NO de atuação sustentada e uma NSAID misturada em um veículo à base de lipídio. A aplicação de tais combinações nas áreas afetadas de um eq³ino, por exemplo o casco e os tecidos ao redor, o qual tenha sido atacado pela laminite, proporciona alívio para os efeitos debilitantes desse estado doloroso e, por vezes, de risco de vida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/752,415 US5891472A (en) | 1996-11-19 | 1996-11-19 | Treatment of equine laminitis |
PCT/US1997/020668 WO1998022090A1 (en) | 1996-11-19 | 1997-11-17 | Treatment of equine laminitis |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9714573A true BR9714573A (pt) | 2002-07-23 |
Family
ID=25026227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9714573-4A BR9714573A (pt) | 1996-11-19 | 1997-11-17 | Tratamento de laminite equina |
Country Status (10)
Country | Link |
---|---|
US (3) | US5891472A (pt) |
EP (1) | EP0946147B1 (pt) |
JP (1) | JP2001509136A (pt) |
AT (1) | ATE326948T1 (pt) |
AU (1) | AU5435998A (pt) |
BR (1) | BR9714573A (pt) |
CA (1) | CA2273183A1 (pt) |
DE (1) | DE69735949T2 (pt) |
ES (1) | ES2263182T3 (pt) |
WO (1) | WO1998022090A1 (pt) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
US6479074B2 (en) | 1996-10-24 | 2002-11-12 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
US5891472A (en) * | 1996-11-19 | 1999-04-06 | Meri Charmyne Russell | Treatment of equine laminitis |
US7914814B2 (en) * | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
US7629384B2 (en) * | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
US6306383B1 (en) * | 1998-09-16 | 2001-10-23 | Wilson T Crandall | Method for topical treatment of scars with protein kinase C inhibitors |
CN1192766C (zh) * | 1998-10-23 | 2005-03-16 | 伊迪亚股份公司 | 开发、测试和使用用于改进的有效负载和可控制性解缔/缔合速度的大分子和复合聚集体的缔合物的方法 |
PT1031346E (pt) | 1999-01-27 | 2002-09-30 | Idea Ag | Vacinacao nao invasiva atraves da pele |
DK1031347T3 (da) | 1999-01-27 | 2002-07-08 | Idea Ag | Transnasal transport/immunisering med meget tilpasselige bærere |
AU5409699A (en) * | 1999-07-05 | 2001-01-22 | Idea Ag | A method for the improvement of transport across adaptable semi-permeable barriers |
JP2004506028A (ja) | 2000-08-11 | 2004-02-26 | ホイットロック,デイビッド アール. | 一酸化窒素及び一酸化窒素前駆体の生産性を高めるアンモニア酸化細菌を含有する化合物並びにそれを利用する方法 |
JP2002136025A (ja) * | 2000-10-26 | 2002-05-10 | Mitsubishi Electric Corp | 電磁機器 |
US6780849B2 (en) | 2000-12-21 | 2004-08-24 | Scimed Life Systems, Inc. | Lipid-based nitric oxide donors |
US6833139B1 (en) * | 2002-01-09 | 2004-12-21 | Ferndale Laboratories, Inc. | Composition and method for the treatment of anorectal disorders |
CN1308438C (zh) * | 2002-01-11 | 2007-04-04 | 大卫·R·怀特洛克 | 含有氨氧化细菌的化合物以及使用的方法 |
US20040018237A1 (en) | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
US20040092819A1 (en) * | 2002-08-16 | 2004-05-13 | Hmt High Medical Technologies Ag | Method for treating laminitis in horses, ponies and other equines with acoustic waves |
US20040105881A1 (en) * | 2002-10-11 | 2004-06-03 | Gregor Cevc | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
US6936273B2 (en) * | 2002-12-20 | 2005-08-30 | Idexx Laboratories, Inc. | Liposomal analgesic formulation and use |
CA2539974A1 (en) * | 2003-09-26 | 2005-04-07 | David R. Whitlock | Methods of using ammonia oxidizing bacteria |
CA2556967A1 (en) * | 2004-02-23 | 2005-09-09 | Strategic Science & Technologies, Llc | Topical delivery of a nitric oxide donor to improve body and skin appearance |
CA2563678A1 (en) * | 2004-04-19 | 2005-11-03 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US20110028548A1 (en) * | 2004-04-19 | 2011-02-03 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US20090105336A1 (en) * | 2004-04-19 | 2009-04-23 | Strategic Science & Technologies, Llc | Beneficial Effects of Increasing Local Blood Flow |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US20060078580A1 (en) * | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US7740875B2 (en) * | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US20080095722A1 (en) * | 2004-11-12 | 2008-04-24 | Idea Ag | Extended Surface Aggregates in the Treatment of Skin Conditions |
CA2588119A1 (en) * | 2004-11-17 | 2006-05-26 | Lindsey Berkson | Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations |
US7731993B2 (en) * | 2004-11-17 | 2010-06-08 | Lindsey Berkson | Composition for treating a dermal anomaly |
EP3556401A1 (en) | 2005-05-27 | 2019-10-23 | The University of North Carolina at Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US7744928B2 (en) * | 2006-04-14 | 2010-06-29 | Advanced Cardiovascular Systems, Inc. | Methods and compositions for treatment of lesioned sites of body vessels |
US8221690B2 (en) | 2007-10-30 | 2012-07-17 | The Invention Science Fund I, Llc | Systems and devices that utilize photolyzable nitric oxide donors |
US7862598B2 (en) | 2007-10-30 | 2011-01-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
US20090112197A1 (en) | 2007-10-30 | 2009-04-30 | Searete Llc | Devices configured to facilitate release of nitric oxide |
US8642093B2 (en) | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
US20100292280A1 (en) * | 2007-04-15 | 2010-11-18 | Oron Zachar | Anti-pyretic vasodilators |
US8877508B2 (en) | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
US7897399B2 (en) | 2007-10-30 | 2011-03-01 | The Invention Science Fund I, Llc | Nitric oxide sensors and systems |
US10080823B2 (en) | 2007-10-30 | 2018-09-25 | Gearbox Llc | Substrates for nitric oxide releasing devices |
US7846400B2 (en) * | 2007-10-30 | 2010-12-07 | The Invention Science Fund I, Llc | Substrates for nitric oxide releasing devices |
US8980332B2 (en) | 2007-10-30 | 2015-03-17 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
AU2009264307A1 (en) * | 2008-06-24 | 2009-12-30 | Intervet International B.V. | Pharmaceutical transdermal compositions and method for treating inflammation in cattle |
US20100227895A1 (en) * | 2009-03-05 | 2010-09-09 | Mpco- The Magic Powder Company | Method for treating equine laminitis |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
EP3045171A1 (en) | 2009-06-24 | 2016-07-20 | Strategic Science & Technologies, LLC | Topical composition |
US9072659B2 (en) | 2009-06-24 | 2015-07-07 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
BR112012003792B1 (pt) | 2009-08-21 | 2020-05-19 | Novan Inc | composição tópica, e, uso da composição tópica |
CN102695528B (zh) | 2009-08-21 | 2016-07-13 | 诺万公司 | 创伤敷料、其使用方法及其形成方法 |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
WO2012092523A1 (en) | 2010-12-29 | 2012-07-05 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
CN114668851A (zh) | 2010-12-29 | 2022-06-28 | 战略科学与技术有限责任公司 | 勃起功能障碍和其它适应症的治疗 |
WO2012118829A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same |
CA2830298C (en) * | 2011-03-17 | 2016-08-16 | Transdermal Biotechnology, Inc. | Topical nitric oxide systems comprising lecithin and methods of use thereof |
US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
WO2014163030A1 (ja) | 2013-04-01 | 2014-10-09 | 第一三共株式会社 | 馬の炎症治療のための製剤 |
US10517817B2 (en) | 2013-05-09 | 2019-12-31 | Syk Technologies, Llc | Deep topical systemic nitric oxide therapy apparatus and method |
US11225640B2 (en) | 2014-04-15 | 2022-01-18 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of psoriasis |
WO2015160911A2 (en) | 2014-04-15 | 2015-10-22 | Aobiome Llc | Ammonia-oxidizing nitrosomonas eutropha strain d23 |
US10052348B2 (en) | 2016-01-27 | 2018-08-21 | Syk Technologies, Llc | Nitric oxide topical application apparatus and methods |
US11344508B2 (en) | 2016-11-09 | 2022-05-31 | Provita Eurotech Ltd | Antimicrobial formulations for the improved treatment of veterinary hoof infections |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2440371A1 (fr) * | 1978-10-31 | 1980-05-30 | Fisons Ltd | Nouveaux composes azotes heterocycliques, des compositions pharmaceutiques en contenant et des procedes pour les preparer |
IE54286B1 (en) * | 1983-01-18 | 1989-08-16 | Elan Corp Plc | Drug delivery device |
CA1319886C (en) * | 1987-02-03 | 1993-07-06 | Alberto Ferro | Mixed micelle solutions |
CH681427A5 (pt) * | 1987-07-01 | 1993-03-31 | Zambon Spa | |
CH680223A5 (pt) * | 1989-07-17 | 1992-07-15 | Pier Luigi Prof Dr Luisi | |
DE4305881C1 (de) * | 1993-02-26 | 1994-03-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung |
WO1995006467A1 (en) * | 1993-08-28 | 1995-03-09 | The University Of Sheffield | Treatment of laminitis |
GB2292520B (en) * | 1994-08-25 | 1998-09-02 | Univ Sheffield | Transdermal dressings for animals |
US5543430A (en) * | 1994-10-05 | 1996-08-06 | Kaesemeyer; W. H. | Method and formulation of stimulating nitric oxide synthesis |
US5891472A (en) * | 1996-11-19 | 1999-04-06 | Meri Charmyne Russell | Treatment of equine laminitis |
-
1996
- 1996-11-19 US US08/752,415 patent/US5891472A/en not_active Expired - Fee Related
-
1997
- 1997-08-19 US US08/914,230 patent/US6045827A/en not_active Expired - Fee Related
- 1997-11-17 WO PCT/US1997/020668 patent/WO1998022090A1/en active IP Right Grant
- 1997-11-17 AT AT97948262T patent/ATE326948T1/de not_active IP Right Cessation
- 1997-11-17 DE DE69735949T patent/DE69735949T2/de not_active Expired - Fee Related
- 1997-11-17 EP EP97948262A patent/EP0946147B1/en not_active Expired - Lifetime
- 1997-11-17 AU AU54359/98A patent/AU5435998A/en not_active Abandoned
- 1997-11-17 JP JP51979898A patent/JP2001509136A/ja not_active Withdrawn
- 1997-11-17 ES ES97948262T patent/ES2263182T3/es not_active Expired - Lifetime
- 1997-11-17 BR BR9714573-4A patent/BR9714573A/pt unknown
- 1997-11-17 CA CA002273183A patent/CA2273183A1/en not_active Abandoned
-
1999
- 1999-06-16 US US09/333,974 patent/US6287601B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE326948T1 (de) | 2006-06-15 |
DE69735949T2 (de) | 2007-01-04 |
WO1998022090A1 (en) | 1998-05-28 |
JP2001509136A (ja) | 2001-07-10 |
AU5435998A (en) | 1998-06-10 |
ES2263182T3 (es) | 2006-12-01 |
EP0946147B1 (en) | 2006-05-24 |
US6287601B1 (en) | 2001-09-11 |
US6045827A (en) | 2000-04-04 |
US5891472A (en) | 1999-04-06 |
DE69735949D1 (de) | 2006-06-29 |
EP0946147A1 (en) | 1999-10-06 |
CA2273183A1 (en) | 1998-05-28 |
EP0946147A4 (en) | 2001-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9714573A (pt) | Tratamento de laminite equina | |
DE69703294T2 (de) | Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten | |
TR27992A (tr) | Suda veya alkolde cözünebilen veya dagilabilen silikon asili termoplastik elastomerik kopolimerler ve bunlari iceren sac ve cilt bakim bilesimleri. | |
SI0882021T1 (en) | New phenanthridines | |
DK0744944T3 (da) | Transdermale terapeutiske systemer indeholdende kønssterioder | |
TR199800232T1 (xx) | Piritroitlerin aktif bile�im kombinezonlar� ve b�cek geli�im inhibit�rleri. | |
MXPA97002401A (es) | Agente antiinflamatorio para uso externo. | |
ATE169445T1 (de) | Verwendung von gelformulierungen als beizmittel | |
PT1039912E (pt) | Agentes angiostaticos e composicoes para tratar glaucoma glc1a | |
MX9306295A (es) | Composiciones farmaceuticas para tratar sintomas de resfriado. | |
PT766557E (pt) | Composicoes de aplicacao topica compreendendo n-acetil-cisteina | |
DE69922684D1 (de) | Verwendung von 2-methoxyestradiol als fungizide | |
BR9714839A (pt) | Composições antitranspirantes em bastão de gel sólido | |
ES2104133T3 (es) | Composiciones cosmeticas o farmaceuticas que contienen glicerofosfolipidos desacilados para uso topico. | |
CA2408541A1 (en) | Treating eczema and/or psoriasis | |
EP1210937A3 (en) | Device for topical treatment of acne and its method of manufacture | |
DK0613368T3 (da) | Hudregenererende kosmetisk sammensætning | |
ATE326520T1 (de) | Teilchen für flüssige zubereitungen | |
DK1054681T3 (da) | Veterninærmedicinsk anvendelse af kombinationer af aktive midler bland antibiotika og terpenholdige planteekstrakter | |
DE69426986T2 (de) | Behandlung von laminitis | |
NO20012631D0 (no) | Trebevarende formuleringer | |
ATE338768T1 (de) | Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression | |
TR199802703T2 (xx) | HIV tedavisinde Vx478, Zidov�din, ve/veya 1592U89 i�eren kombinasyonlar�n kullan�m�. | |
DE69821228D1 (de) | Selektive mmp inhibitoren mit verringerten nebenwirkungen | |
DE69927815D1 (de) | Inositolphosphoglycan und ribose zur behandlung von ischämischen-reperfusionschaden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCP | Transfer pending | ||
B25B | Requested transfer of rights rejected | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |